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based on the published literature about economic burden of chronic hepatitis B. A 
discounting rate at 3% was used to discount medical costs happened at different years. 
A univariate sensitivity analysis was performed to understand the key drivers and 
general sensitivity of the model. RESULTS: The model results showed that the utiliza-
tion of peginterferon alfa-2a treatment for HBeAg-positive CHB can prolong 0.672 
QALYs, compared to the entecavir treatment. The total cost per patient treated with 
peginterferon alfa-2a was US$28,093, and US$25,768 for patient treated with ente-
cavir. The discounted incremental cost per QALY gained for pegainterferon alfa-2a 
treatment was US$3,461. CONCLUSIONS: The results of the model suggest that 
pegainterferon alfa-2a improves health outcomes in a cost-effective manner compared 
with entecavir in the treatment of HBeAg-positive chronic hepatitis B in China.
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OBJECTIVES: To conduct a cost-utility analysis of rotavirus vaccine (Rotarix®) for 
infants in Japan. METHODS: A Markov model was constructed to analyze costs and 
Quality-Adjusted Life Years (QALYs) from the societal perspective. We captured costs 
and outcomes until infants reached ﬁve years old. In the Markov model, one month 
was set as one cycle. Both costs and utility were discounted at 3 percent annually. 
Based on suggestions from expert of pediatric infectious diseases, various factors have 
relationship with immunological status, such as breastfeeding and communal living, 
were adopted to our model. The health care cost were derived from Japanese data. 
Effectiveness of vaccination was derived from clinical trial in Europe. Various sensitiv-
ity analyses, both univariate and probabilistic ones, were conducted. We used QALY 
for outcome measurement. Quality weight for each status was derived from the foreign 
literature. RESULTS: In the basecase analysis, Rotarix® increased both costs and 
QALYs, compared to no vaccination. Rotarix® would increase costs of JPY 9253 
(US$93, USD1  JPY100). and increase 0.0024 QALY in infants in Japan. ICER for 
Rotarix was JPY3.8 million (US$D38,000) per QALY gained. Sensitivity analyses 
suggested the robustness of the results. When we set threshold for 1QALY to JPY5.0 
million (US$50,000), the probability of the acceptance of Rotarix was 83%. CON-
CLUSIONS: Rotarix® for infants in Japan, is thought to be cost-effective.
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OBJECTIVES: In the past decade, infection with the hepatitis C virus has turned out 
to be a major health threat among speciﬁc risk groups. Given the silent nature, but 
serious long term complications of hepatitis C infection, case ﬁnding is as difﬁcult as 
it is vital. To improve hepatitis C case ﬁnding, the need for public campaigns is 
increasingly recognized. Three pilot campaigns have been performed in The Nether-
lands: a campaign aimed at the general population, the same campaign extended with 
a support programme for primary care and a campaign speciﬁcally aimed at hard drug 
users. The aim of this study is to evaluate cost-effectiveness (from a health care per-
spective) of these campaigns, when performed on a national scale. METHODS: 
Information gained during the pilot studies and estimations for costs for a national 
campaign were used to build a mathematical model to estimate the incremental cost-
effectiveness ratios. The natural history of hepatitis C was described by a previously 
developed Markov model, that was adapted to the current Dutch situation. RESULTS: 
For the ‘support campaign’ the discounted incremental cost per tested person is a326 
with an associated gain of 0.022 QALYs (^8 days). The resulting ICER is a14,980 
per QALY. For the ‘drug users campaign’ the discounted incremental cost per tested 
person is a1960 with an associated gain of 0.168 QALYs. The resulting ICER is 
a11,747 per QALY. CONCLUSIONS: The campaign aimed at the general public 
without support for primary care did not improve case ﬁnding and was therefore not 
cost-effective. Considering a Dutch cut-off point of an ICER of a20,000 as a favour-
able cost-effectiveness ratio, both the campaign accompanied by additional support 
for primary care and the campaign aimed at hard drug users are to be considered a 
cost-effective investment to improve case ﬁnding and prevent future complications of 
hepatitis C.
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OBJECTIVES: To evaluate the cost-utility of pneumococcal conjugate vaccines in 
Germany (societal perspective). METHODS: An age-compartmental, one-year, steady-
state population model was developed to estimate annual incremental cost savings 
(CS) and QALYs gained (QG) for pneumococcal non-typeable  Haemophilus inﬂuen-
zae protein-D conjugate vaccine (PHiD-CV) and 13-valent pneumococcal candidate     
vaccine (PCV-13) compared with PCV-7. Two scenarios were evaluated: one consider-        
ing effectiveness against Streptococcus pneumoniae (Sp) only, another including effec-
tiveness against non-typable Haemophilus inﬂuenzae (NTHi) in acute otitis media 
(AOM) for PHiD-CV. Invasive pneumococcal disease (IPD) serotype-speciﬁc effective-     
ness data were taken from US studies; effectiveness data for pneumonia were derived 
from the PCV-7 Kaiser Permanente trial and for AOM from two randomized Euro-
pean clinical trials. Epidemiological data and utility decrements were taken from 
published literature. DRGs (2008) provided the basis for stationary cost data, while 
ambulatory cost for pneumonia and AOM was estimated by experts. Other parameters 
included: vaccination coverage (90%), discount rate (3%), age-speciﬁc IPD herd 
immunity (30%[18], 19%[18–64], 38%[65]), price parity for all vaccines. 
RESULTS: In the scenario considering effectiveness against Sp only, PCV-13 domi-
nated both PCV-7 (CS: 5.8mna, QG: 260.6) and PHiD-CV (CS: a3.2mn, QG: 159.9). 
In the scenario including effectiveness against NTHi in AOM, PHiD-CV dominated 
both PCV-7 (CS: a9.0mn, QG: 637.1) and PCV-13 (CS: a3.2mn, QG: 376.5). Results 
were robust in both one-way and probabilistic sensitivity analysis. CONCLUSIONS: 
Including effectiveness against NTHi in AOM in the analysis, the protein-D conjugate 
vaccine PHiD-CV is cost saving compared to the CRM conjugate vaccines PCV-7 and 
the candidate vaccine PCV-13.
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OBJECTIVES: This study aims to estimates cost and effectiveness of itraconazole and 
posaconazole in prophylaxis of invasive fungal infections (IFI) patients with neutro-
penia in Spain. METHODS: From the payer’s perspective, a Markov model was 
developed to represent the transition of a neutropenic cohort of patients with prophy-
laxis of IFI through different health states: patient in prophylaxis of IFI, IFI, no-IFI, 
death by IFI and death by some other causes. Efﬁcacy data on incidence of proven or 
probable IFI, survival data and health-state utilities were obtained from published 
studies. Deterministic results were estimated and a probabilistic sensitivity analysis 
was conducted using statistical distributions in order to capture parameter uncertainty 
in the decision model. Treatment costs were obtained from a panel of clinical experts. 
Costs were referred to year 2009 and a time horizon of 1 year was chosen. Results 
were presented as expected cost per quality adjusted life years (QALYs) gained and 
represented in cost-effectiveness acceptability curves (CEACs). RESULTS: In the deter-
ministic analysis, the expected cost per patient was greater in the posaconazole cohort 
(a19,522) in comparison with itraconazole cohort (a19,508). The estimated effective-
ness was the same (0.42 QALY gained) in both cohorts. In the probabilistic analysis 
CEACs showed that the probability that the treatment with itraconazole was more 
cost-effective than the treatment with posaconazole using alternative values for the 
maximum value that the health service would be willing to pay for an additional 
QALY in prophylaxis of IFI was greater in the itraconazole cohort. CONCLUSIONS: 
When itraconazole has been compared to posaconazole we may conclude that the ﬁrst 
one is a dominant strategy. Results from probabilistic sensibility analysis show that 
the choice of optimal strategy is independent on the maximum that the health service 
is prepared to pay per additional QALY gained because itraconazole has a greater 
probability of being cost-effective for all threshold values.
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OBJECTIVES: DUET-1 and DUET-2 are two identically designed, randomized,        
double-blind, placebo-controlled, Phase-III-trials, which have demonstrated superior-
ity of etravirine (ETR) background regimen (BR) (ETR-arm) versus placebo  BR 
(PLAC-arm) in HIV-1-infected, treatment-experienced patients. Hospitalisation events 
and duration of hospital stay were recorded for each patient. The objective of this 
study was to calculate the costs of hospitalisations observed in the DUET trials for 
the German health care setting. METHODS: The number and duration of hospitalisa-     
tions were analyzed at 48 weeks. Hospitalisation rates were analyzed by negative 
binomial regression. Hospital costs in the German setting were calculated by applying 
the German-DRG system for each patient based on individually recorded disease 
characteristics and diagnoses. For all psychiatric admissions, where DRGs are not 
applicable, the ﬁxed daily rate was used (a241/d). RESULTS: A total of 1203 patients  
were included: 599 vs 604 in the ETR- versus PLAC-arms. Numbers (%) of patients 
hospitalised were 105 (17.5%) vs. 139 (23.0%) for ETR-arm vs. PLAC-arm, respec-
tively (p  0.0006). The mean durations of stays for second (13.5d) or subsequent 
hospitalisations (15.6d) were longer than for ﬁrst admission (10.4d) overall, and for 
all stays were longer and therefore more expensive in PLAC-arm (12.3d) vs. ETR-arm 
(11.0d). Patients with baseline-CD4-cell-counts of 50 cells/mm3 had a statistically 
signiﬁcant lower hospitalisation rate in the ETR-arm versus PLAC-arm (p  0.0001). 
Total hospital days observed during the 48-week follow-up period were 1702 vs. 2747 
for ETR-arm vs. PLAC-arm. Calculated total hospital costs were a633.238 (ETR-arm) 
vs. a975,750 (PLAC-arm), resulting in a mean saving for hospitalisation costs of a572 
for each patient treated within the ETR-arm. CONCLUSIONS: At Week 48, ETR     
